STA
VRTX icon

Summit Trail Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Summit Trail Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.24M Buy
7,247
+2,190
+43% +$1.02M 0.05% 279
2025
Q4 		$2.29M Sell
5,057
-427
-8% -$184K 0.04% 331
2025
Q3 		$2.15M Sell
5,484
-387
-7% -$162K 0.03% 409
2025
Q2 		$2.61M Buy
5,871
+588
+11% +$271K 0.04% 213
2025
Q1 		$2.56M Buy
5,283
+874
+20% +$407K 0.08% 73
2024
Q4 		$1.78M Buy
4,409
+1,145
+35% +$531K 0.07% 90
2024
Q3 		$1.52M Buy
3,264
+383
+13% +$184K 0.04% 200
2024
Q2 		$1.35M Buy
2,881
+372
+15% +$161K 0.04% 187
2024
Q1 		$1.05M Buy
2,509
+410
+20% +$173K 0.03% 212
2023
Q4 		$854K Sell
2,099
-260
-11% -$96K 0.03% 200
2023
Q3 		$820K Buy
2,359
+692
+42% +$242K 0.03% 191
2023
Q2 		$587K Buy
1,667
+944
+131% +$318K 0.02% 234
2023
Q1 		$228K Buy
+723
New +$217K 0.01% 367
2019
Q1 		– Sell
-1,396
Closed -$231K – 133
2018
Q4 		$231K Sell
1,396
-1,695
-55% -$294K 0.08% 93
2018
Q3 		$596K Buy
3,091
+274
+10% +$48.8K 0.13% 89
2018
Q2 		$479K Sell
2,817
-6,512
-70% -$1.01M 0.17% 74
2018
Q1 		$956K Buy
9,329
+1,140
+14% +$186K 0.16% 137
2017
Q4 		$1.34M Buy
+8,189
New +$1.21M 0.17% 120

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Summit Trail Advisors's VRTX Position: Q1 2026 in Review

Summit Trail Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 43% in Q1 2026, buying an estimated $1.02M and bringing the position to 7,247 shares worth $3.24M. The position accounts for 0.05% of the portfolio, ranked #279.

Summit Trail Advisors first reported a position in VRTX in Q4 2017 and has held it in 18 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Summit Trail Advisors held 7,247 shares of Vertex Pharmaceuticals worth $3.24M as of Q1 2026.
  • Summit Trail Advisors bought 2,190 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.02M.
  • Vertex Pharmaceuticals made up 0.05% of Summit Trail Advisors's portfolio in Q1 2026, its #279 holding.
  • Summit Trail Advisors first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 18 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Summit Trail Advisors's 13F filing for Q1 2026, filed 12 May 2026.